Advertised offers in this category cannot be compared as advertised. Each headline figure is a discount applied to one line item for a limited window, and rival offers discount different lines. The only figure that compares is twelve months of everything, priced at the dose most patients settle on rather than the dose everyone starts at.
By Dr. Shiv K. Goel, MD, FACP
A headline price is a coupon, not a price
Look at what a promotional figure is attached to before treating it as the cost of anything. On the pricing terms published at ro.co in July 2026, the membership and the medication are stated as two separate charges, and each carries its own promotional structure. Membership is quoted at $39 for a first month and then $74 to $149 a month depending on the length of the plan chosen. Medication prices are published per dose, with individual doses carrying time-limited reductions that name a sign-up deadline.
A competing brand may put its promotion on the drug and leave its access fee at full rate. A third may fold both into one number. A fourth may quote a price that assumes an insurance benefit that not every viewer has. None of those four headline figures answers the same question, so ranking them against each other produces a ranking of marketing choices rather than a ranking of value.
The field to normalize is wider than one advertiser. Ro competes with Hims and Hers, Henry Meds, and Sesame on the membership side, while manufacturer channels such as LillyDirect and NovoCare sell the branded drug at a fixed cash rate. A provider like HealthRX lists its own membership terms and cash prices for GLP-1 medications, and running each of these offers through the same twelve-month calculation is what turns a wall of headline figures into a ranking that means something.
Normalize before comparing, using four inputs
The arithmetic that does compare needs four inputs from every candidate, and all four are usually obtainable from a published pricing page.
First, the ongoing access fee after any introductory month, at the plan length actually intended. Second, the medication price at maintenance strength rather than at the starting dose. Third, anything billed on use, such as laboratory work or consults beyond an included allowance. Fourth, the commitment term, because a lower monthly rate that requires prepaying six or twelve months is a different product from the same rate billed month to month.
Multiply the first two by twelve, add the third, and note the fourth beside the total rather than inside it. That single number is comparable across providers. A first-month figure is not, and a first-month figure is what almost every advertisement is built around.
| Offer type | What the advertised figure usually covers | What it leaves out | Question that normalizes it |
|---|---|---|---|
| Manufacturer direct self-pay channel | The drug alone, at a published cash rate | Any clinical service or prescriber relationship | Who writes and manages the prescription |
| Telehealth membership plus cash medication | An introductory access fee | The drug, which is billed on its own schedule | What both lines cost in month six |
| Insurance-routed telehealth | Access plus benefits advocacy | The copay, which the plan sets, not the platform | What happens if coverage is denied |
| Compounded cash-pay program | One blended monthly figure | FDA approval, which compounded products do not carry | What changes as the dose rises |
| Pharmacy discount card | A percentage off a retail cash price | Clinical oversight and continuity | Whether the price holds at every dose |
What a deadline on an offer actually tells you
Promotional terms in this category frequently carry two qualifiers worth noticing: a sign-up deadline and a dose restriction. Ro’s published medication pages, for example, attach limited-time reductions to specific strengths and state a date by which a patient must sign up to qualify. Both qualifiers point the same way. A reduction that applies only to the lowest strengths lowers the entry cost rather than the cost of treatment, because dosing in this class escalates by design.
That is not a criticism of the practice, which is disclosed on the page. It is a reason to read the qualifier as part of the price. An offer valid on a starting dose is a discount on the first few months of a regimen that trial evidence suggests works at higher strengths held over time.
The variable that outranks price
Total cost only matters once the clinical question is settled, and the clinical differences between agents are real. A large retrospective analysis comparing semaglutide and tirzepatide in adults with overweight or obesity found greater weight reduction with tirzepatide. In a randomized comparison of weekly semaglutide against daily liraglutide, the weekly agent produced greater reduction over 68 weeks. Continuation also matters: SURMOUNT-4 showed that continued tirzepatide maintained reduction while withdrawal was followed by regain.
Those findings come from different studies with different designs and populations and should not be read as one head-to-head tournament. They do establish that the choice of agent and the length of treatment move outcomes more than a promotional month does. An offer that is cheaper for eight weeks and unaffordable at month nine is not the cheaper offer.
Business model changes the shape of the quote as much as the size of it. A cash-pay compounded provider such as formblends.com typically states a single monthly figure covering supervision and product together, which makes the twelve-month arithmetic straightforward, though the product itself is not FDA-approved and the agency has published its concerns about unapproved GLP-1 drugs marketed for weight loss.
Where insurance rewrites the whole comparison
Before any cash figure is compared, coverage is worth checking, because a covered prescription is priced by a plan rather than by a platform. Medicare drug coverage rules and plan formularies determine what a beneficiary pays, and commercial plans vary widely on whether weight management drugs are a covered benefit at all. Self-pay terms in this category also commonly require a patient to agree that the spend will not be submitted for reimbursement or applied toward a deductible, which widens the real gap between a cash price and a copay beyond what the two numbers suggest.
Frequently asked questions
Why do advertised prices from two providers never match up?
Because they are quoting different line items. One discounts an access fee, another discounts a starting dose, another quotes a bundled figure. Until all of them are converted to twelve months of access plus twelve months of medication at maintenance strength, the headline numbers describe marketing structure rather than cost.
Is a prepaid annual plan the better deal?
It lowers the monthly rate and removes the option to leave cheaply, so it is a good deal only if treatment continues. Evidence on continuation shows that stopping is generally followed by regain, which argues for planning around a longer horizon, but circumstances and tolerability still change.
Does a lower price mean a lesser service?
Not reliably. Price differences in this category track business model more than service depth. A manufacturer self-pay channel sells the drug with no clinical wrapper, while a membership platform sells the wrapper and bills the drug separately. Compare what is included, then compare the totals.
What single question exposes the most about an offer?
Ask what a full month costs at maintenance dose after every introductory period has ended. Any provider can answer it from published material, the answer is not promotional, and it is the number that will appear on a statement for most of the time treatment continues.
Sources
- Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. https://pubmed.ncbi.nlm.nih.gov/38976257/
- Continued treatment with tirzepatide for maintenance of weight reduction, SURMOUNT-4. https://pubmed.ncbi.nlm.nih.gov/38078870/
- Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight, STEP 8. https://pubmed.ncbi.nlm.nih.gov/35015037/
- Pharmacotherapy for obesity management in adults, 2025 clinical practice guideline update. https://pubmed.ncbi.nlm.nih.gov/40789597/
- CMS, Medicare prescription drug coverage. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
- Medicare, drug coverage under Part D. https://www.medicare.gov/drug-coverage-part-d
- DailyMed, Foundayo prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=FOUNDAYO
- FDA, concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA, compounding and the FDA questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Ro weight loss pricing and medication dose pages, ro.co, retrieved 24 July 2026.
